CN103585205B - The application of a kind of Chrysosplenium extract in preparation treatment diabetes medicament - Google Patents
The application of a kind of Chrysosplenium extract in preparation treatment diabetes medicament Download PDFInfo
- Publication number
- CN103585205B CN103585205B CN201310525365.1A CN201310525365A CN103585205B CN 103585205 B CN103585205 B CN 103585205B CN 201310525365 A CN201310525365 A CN 201310525365A CN 103585205 B CN103585205 B CN 103585205B
- Authority
- CN
- China
- Prior art keywords
- extract
- grass
- golden waist
- ethanol
- waist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 155
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 241001092413 Chrysosplenium Species 0.000 title description 4
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 103
- 239000011347 resin Substances 0.000 claims abstract description 45
- 229920005989 resin Polymers 0.000 claims abstract description 45
- 238000001179 sorption measurement Methods 0.000 claims abstract description 35
- 238000000605 extraction Methods 0.000 claims abstract description 33
- 229940079593 drug Drugs 0.000 claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 118
- 239000002904 solvent Substances 0.000 claims description 32
- 241001505935 Phalaenopsis Species 0.000 claims description 24
- 239000012141 concentrate Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000002791 soaking Methods 0.000 claims description 15
- 241000745988 Phyllostachys Species 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 6
- 239000012676 herbal extract Substances 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 208000031971 Yin Deficiency Diseases 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241001506047 Tremella Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- -1 paeonol polysaccharide Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- XVVBVBKVMMNZHB-LFYBBSHMSA-N 9-[(e)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]furo[3,2-g]chromen-7-one Chemical compound C=12OC=CC2=CC=2C=CC(=O)OC=2C=1OC\C=C(/C)CC1OC(=O)C(C)=C1 XVVBVBKVMMNZHB-LFYBBSHMSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000000588 Hericium erinaceus Species 0.000 description 1
- 235000007328 Hericium erinaceus Nutrition 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241001647091 Saxifraga granulata Species 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- UILPJVPSNHJFIK-UHFFFAOYSA-N p-methoxy-o-hydroxyacetophenone Natural products COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 239000010019 qianjin huanglian Substances 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960003271 rosiglitazone maleate Drugs 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种金腰草提取物的新用途,该新用途是金腰草提取物在制备治疗糖尿病药物中的应用。所述金腰草提取物是按如下方法制备的:以金腰草为原料,提取后,采用两次大孔吸附树脂纯化技术分别得到金腰草提取物A、金腰草提取物B、金腰草提取物C,按一定比例混合,即为金腰草提取物。本发明所提供的金腰草提取物对制备治疗糖尿病药物具有重要意义。The invention discloses a new application of the extract of the golden waist grass, and the new use is the application of the golden waist grass extract in the preparation of medicines for treating diabetes. The golden waist extract is prepared according to the following method: golden waist grass is used as raw material, and after extraction, two macroporous adsorption resin purification techniques are used to obtain golden waist grass extract A, golden waist grass extract B, golden waist grass Herbal extract C, mixed according to a certain ratio, is the extract of Golden waist. The golden waist grass extract provided by the invention is of great significance for the preparation of medicines for treating diabetes.
Description
技术领域 technical field
本发明属于医药领域,涉及一种中药材提取物在制备治疗糖尿病药物中的应用,具体是涉及一种金腰草提取物在制备治疗糖尿病药物中的应用。 The invention belongs to the field of medicine, and relates to the application of an extract of traditional Chinese medicinal materials in the preparation of medicines for treating diabetes, in particular to the application of an extract of golden waist grass in the preparation of medicines for treating diabetes.
背景技术 Background technique
随着世界人口的老龄化,糖尿病已经成为一种常见病、多发病,在工业发达国家其发病率呈上升趋势。据统计,全世界约有1.5亿糖尿病患者,80%为非胰岛素依赖型糖尿病(2型),其中我国约有3000万。由糖尿病并发症引起的死亡人数在发达国家已是继心脑血管疾病、癌症之后列第三位,引起了世界各国的高度重视,纷纷对糖尿病的发病机制、药物防治等进行研究。由于1型糖尿病病因已基本明确,只需补充胰岛素即可,而2型糖尿病则较复杂,目前我国医学界对其采取的是包括饮食疗法、药物治疗与其它辅助疗法的综合治疗措施。西药虽然层出不穷,但不能从根本上解决问题,而且西药治疗具有一定的副作用及“治疗失效”。中医药治疗糖尿病历史悠久,临床经验丰富,疗效显著,已成为近年来国内外研究热点。中医学对糖尿病的认识与西医不同,中医强调整体观,以阴、阳二者的变化反映疾病的本质。正常机体是“阴平阳秘”,阴阳平衡,即机体内环境维持稳态,糖代谢也维持稳定;并且中药的毒副作用相对较小,病人可长期服用,这是西药所不能比拟的独特的优势。 With the aging of the world's population, diabetes has become a common and frequently-occurring disease, and its incidence is on the rise in industrialized countries. According to statistics, there are about 150 million diabetic patients in the world, 80% of which are non-insulin-dependent diabetes (type 2), of which there are about 30 million in my country. The number of deaths caused by diabetes complications ranks third after cardiovascular and cerebrovascular diseases and cancer in developed countries, which has attracted great attention from all over the world, and researches on the pathogenesis and drug prevention and treatment of diabetes have been carried out one after another. Since the etiology of type 1 diabetes is basically clear, only insulin supplementation is enough, while type 2 diabetes is more complicated. At present, the medical field in my country adopts comprehensive treatment measures including diet therapy, drug therapy and other adjuvant therapies. Although western medicine emerges in an endless stream, it cannot fundamentally solve the problem, and western medicine treatment has certain side effects and "treatment failure". TCM treatment of diabetes has a long history, rich clinical experience, and remarkable curative effect. It has become a research hotspot at home and abroad in recent years. The understanding of diabetes in traditional Chinese medicine is different from that in western medicine. Traditional Chinese medicine emphasizes the holistic view and reflects the essence of the disease through the changes of yin and yang. The normal body is "yin and yang secret", yin and yang are balanced, that is, the internal environment of the body maintains a stable state, and the glucose metabolism also maintains stability; and the toxic and side effects of traditional Chinese medicine are relatively small, and patients can take it for a long time. This is a unique advantage that western medicine cannot match. .
中医认为糖尿病是由肺、胃、肾三脏热灼阴亏,水谷转输失常所致。其基 Traditional Chinese medicine believes that diabetes is caused by burning yin deficiency in the lungs, stomach, and kidneys, and abnormal water and grain transfer. Its base
本病机为阴津亏耗,燥热偏盛,肾阴亏虚为本,肺胃燥热为标,病久则阴损气耗阳伤,而致气阴两伤,阴阳俱虚,脉络瘀阻,筋脉失养,脏腑受损,渐致出现一系列兼症。 The pathogenesis is depletion of yin and fluid, excess of dryness and heat, deficiency of kidney yin as the root, dryness and heat of the lung and stomach as the standard, long-term illness leads to loss of yin, depletion of qi and injury of yang, resulting in damage to both qi and yin, deficiency of both yin and yang, blood stasis in the veins, The tendons and arteries are not nourished, the internal organs are damaged, and a series of concurrent diseases gradually appear.
糖尿病的病程是阴损及阳的过程。以阴辨证,从轻到重,则是阴虚—气阴两虚—阴阳两虚的转化。而脉络瘀阻贯穿于本病及兼症的全过程。 The course of diabetes is a process of yin damage and yang. Based on yin differentiation, from mild to severe, it is the transformation of yin deficiency - deficiency of both qi and yin - deficiency of both yin and yang. And blood stasis runs through the whole process of primary disease and concurrent disease.
近年来,有的学者探讨了糖尿病中医辨证分型与临床生化指标的关系。从胰岛功能、血脂水平、血浆性激素、皮质激素水平、免疫功能机血液流变学等变化,观察消渴病分型与以上指标改变的相关性,发现各种指标的异常变化,从轻到重,多随阴虚—气阴两虚—阴阳两虚方向发展。体现了中西医结合探讨消渴病分型的物质基础。 In recent years, some scholars have explored the relationship between TCM syndrome differentiation and clinical biochemical indicators of diabetes. From the changes of pancreatic islet function, blood lipid level, plasma sex hormone, corticosteroid level, immune function and blood rheology, etc., observe the correlation between the type of diabetes and the changes of the above indicators, and find the abnormal changes of various indicators, ranging from mild to severe , mostly develops in the direction of deficiency of yin—deficiency of both qi and yin—deficiency of both yin and yang. It embodies the material basis for exploring the classification of diabetes by combining traditional Chinese and Western medicine.
辨证论治是中医理论的精髓。中医根据消渴病的主要病机,辨别燥热与阴虚的标本轻重,用药时重视养阴,有燥热者则须清热,阴阳气血均亏,则阴阳气血并补。根据现代药理概念,对中药抗糖尿病的作用研究主要如下。单味中药:黄连及小檗碱、苦瓜、人参、黄芪、黄芩、桑叶、中药多糖(如银耳多糖,银耳孢子多糖、木耳多糖、猴头多糖、紫菜多糖、麦冬多糖、褐藻淀粉(laminarin)、枸杞多糖-X、枸杞多糖-D、番瓜多糖及丹皮多糖等)、水飞蓟素、大黄。此外,口服黄酮类葛根素(puerarin)或黄皮香豆精(clausenacoumarine)对ALX动物的高血糖也有降低作用。中医治疗糖尿病的基本原则可概括为:滋阴清热、益气养阴、补肾健脾及活血化瘀等。常用经典方剂有人参白虎汤、六味地黄丸、八位地黄丸及千金黄连丸等,根据不同证型及上述治则组方或用古方进行加减。 Syndrome differentiation and treatment is the essence of TCM theory. According to the main pathogenesis of diabetes, traditional Chinese medicine distinguishes the severity of dryness and heat and yin deficiency, and pays attention to nourishing yin when taking medicine. If there is dryness and heat, it should be cleared away. According to modern pharmacological concepts, the research on the anti-diabetic effect of traditional Chinese medicine is mainly as follows. Single traditional Chinese medicine: coptis and berberine, bitter gourd, ginseng, astragalus, scutellaria baicalensis, mulberry leaves, traditional Chinese medicine polysaccharides (such as tremella polysaccharides, tremella spore polysaccharides, fungus polysaccharides, Hericium erinaceus polysaccharides, laver polysaccharides, Ophiopogon japonicus polysaccharides, laminarin ), Lycium barbarum polysaccharide-X, Lycium barbarum polysaccharide-D, papaya polysaccharide and paeonol polysaccharide, etc.), silymarin, rhubarb. In addition, oral administration of flavonoids puerarin or clausenacoumarine also reduced hyperglycemia in ALX animals. The basic principles of TCM treatment of diabetes can be summarized as: nourishing yin and clearing away heat, nourishing qi and nourishing yin, nourishing kidney and spleen, promoting blood circulation and removing blood stasis, etc. Commonly used classic prescriptions include Shenbaihu Decoction, Liuwei Dihuang Pills, Bawei Dihuang Pills, and Qianjin Huanglian Pills. According to different syndrome types and the above-mentioned treatment principles, formulas can be formulated or added or subtracted from ancient prescriptions.
金腰草为虎耳草科植物裸茎金腰子ChrysospleniumnudicauleBge.及同属数种植物的干燥全草。秋季采集,除去枯叶,洗净,晒干。收载于《中华人民共和国卫生部药品标准藏药(第一册)》,标准编号:WS3-BC-0061-95。性寒,味苦。具有清热利胆,缓泻下之功效。用于胆热症,发烧,头痛,胆囊炎,胆结石。为泻胆热症常用药物。为我国藏蒙等少数民族地区的常用药物。但有关金腰草的基础研究尚十分有限,使该药材的后续推广和应用受到限制。现代研究关于阿氏蒿的化学成分及药理作用鲜有报道。 Golden waist grass is the dry whole plant of Chrysosplenium nudicaule Bge. and several plants of the same genus. Collect in autumn, remove dead leaves, wash and dry. It is recorded in "Ministry of Health of the People's Republic of China Drug Standard Tibetan Medicine (Volume 1)", standard number: WS3-BC-0061-95. Cold in nature, bitter in the mouth. It has the effects of clearing away heat and promoting gallbladder, and laxative. For biliary fever, fever, headache, cholecystitis, gallstones. Commonly used medicine for diarrhea. It is a commonly used drug in ethnic minority areas such as Tibet and Mongolia. However, the basic research on Golden Waist Grass is still very limited, which limits the subsequent promotion and application of this medicinal material. There are few reports on the chemical constituents and pharmacological effects of Artemisia arborii in modern research.
国内专利检索结果,未见金腰草相关专利。 According to domestic patent search results, there is no patent related to golden waist grass.
上述文献及专利等,尚未见金腰草或金腰草提取物用于制备治疗糖尿病药物的报道。 In the above-mentioned literatures and patents, there is no report on the use of Phalaenopsis or Phalaenopsis extracts for the preparation of drugs for treating diabetes.
发明内容 Contents of the invention
本发明的目的在于提供一种金腰草提取物的在制备治疗糖尿病药物中的应用。 The purpose of the present invention is to provide an application of the extract of Phalaenopsis radix in the preparation of medicaments for treating diabetes.
本发明是通过如下技术方案实现的: The present invention is achieved through the following technical solutions:
本发明所用金腰草为虎耳草科植物裸茎金腰子ChrysospleniumnudicauleBge.及同属数种植物的干燥全草。 The golden waist grass used in the present invention is the dry whole herb of Chrysosplenium nudicaule Bge. and several plants of the same genus.
一种金腰草提取物在制备治疗糖尿病药物中的应用,所述金腰草提取物的制备方法为: An application of a golden waist extract in the preparation of a medicine for treating diabetes, the preparation method of the golden waist extract is:
(1)金腰草,用浓度80%-100%乙醇作为溶剂,在20℃-70℃温浸提取,提取次数为2-6次,每次提取时间为2-8小时,每次溶剂用量为金腰草重量的10-30倍,滤过,得药渣A和提取液,提取液回收乙醇,浓缩,干燥,得金腰草提取物A; (1) Golden waist grass, use ethanol with a concentration of 80%-100% as a solvent, and extract it by warm soaking at 20°C-70°C. The number of extractions is 2-6 times, and the extraction time is 2-8 hours each time. The amount of solvent used each time It is 10-30 times of the weight of Phyllostachys chinensis, filtered to obtain the dregs A and the extract, the extract is recovered with ethanol, concentrated, dried, and the extract A of Phalaenopsis is obtained;
(2)将步骤(1)得到药渣A用浓度0-50%乙醇为溶剂,在30℃-80℃温浸提取,提取次数为2-5次,每次提取时间为1-6小时,每次溶剂用量为金腰草重量的6-20倍,滤过,提取液回收乙醇,浓缩至相对密度d=1.05-1.12,滤过,得药液B; (2) Use 0-50% ethanol as a solvent to extract the dregs A obtained in step (1) by warm soaking at 30°C-80°C. The number of extractions is 2-5 times, and the extraction time is 1-6 hours each time. The amount of solvent used each time is 6-20 times of the weight of Golden Waist Grass, filtered, the extract is recovered with ethanol, concentrated to relative density d=1.05-1.12, filtered to obtain liquid B;
(3)将步骤(2)得到的药液B,通过非极性大孔吸附树脂柱,先用水洗脱,水洗脱液直接通过极性大孔树脂柱,再用浓度60%-95%的乙醇溶液洗脱非极性大孔吸附树脂柱,收集不同浓度乙醇洗脱液,浓缩干燥,即得金腰草提取物B;再用浓度60%-85%的乙醇溶液洗脱极性大孔吸附树脂柱,收集不同浓度乙醇洗脱液,浓缩干燥,即得金腰草提取物C; (3) Pass the drug solution B obtained in step (2) through a non-polar macroporous adsorption resin column, and first elute with water, and the water eluent directly passes through the polar macroporous resin column, and then use a concentration of 60%-95% ethanol solution to elute the non-polar macroporous adsorption resin column, collect ethanol eluents of different concentrations, concentrate and dry, and then obtain Golden Waist Grass Extract B; Hole adsorption resin column, collect ethanol eluents with different concentrations, concentrate and dry, and then get Phalaenopsis extract C;
(4)上述金腰草提取物A、金腰草提取物B、金腰草提取物C,其中一种或两种或三种按一定比例混匀,即得本发明的金腰草提取物。 (4) The above-mentioned Golden Waist Grass Extract A, Golden Waist Grass Extract B, Golden Waist Grass Extract C, one or two or three of them are mixed in a certain proportion to obtain the Golden Waist Grass Extract of the present invention .
金腰草提取物的制备方法为: The preparation method of golden waist grass extract is:
(1)金腰草,用浓度80%-100%乙醇作为溶剂,在20℃-70℃温浸提取,提取次数为2-6次,每次提取时间为2-8小时,每次溶剂用量为金腰草重量的10-30倍,滤过,得药渣A和提取液,提取液回收乙醇,浓缩,干燥,得金腰草提取物A; (1) Golden waist grass, use ethanol with a concentration of 80%-100% as a solvent, and extract it by warm soaking at 20°C-70°C. The number of extractions is 2-6 times, and the extraction time is 2-8 hours each time. The amount of solvent used each time It is 10-30 times of the weight of Phyllostachys chinensis, filtered to obtain the dregs A and the extract, the extract is recovered with ethanol, concentrated, dried, and the extract A of Phalaenopsis is obtained;
(2)将步骤(1)得到药渣A用浓度0-50%乙醇为溶剂,在30℃-80℃温浸提取,提取次数为2-5次,每次提取时间为1-6小时,每次溶剂用量为金腰草重量的6-20倍,滤过,提取液回收乙醇,浓缩至相对密度d=1.05-1.12,滤过,得药液B; (2) Use 0-50% ethanol as a solvent to extract the dregs A obtained in step (1) by warm soaking at 30°C-80°C. The number of extractions is 2-5 times, and the extraction time is 1-6 hours each time. The amount of solvent used each time is 6-20 times of the weight of Golden Waist Grass, filtered, the extract is recovered with ethanol, concentrated to relative density d=1.05-1.12, filtered to obtain liquid B;
(3)将步骤(2)得到的药液B,通过非极性大孔吸附树脂柱,先用水洗脱,水洗脱液直接通过极性大孔树脂柱,再用浓度60%-95%的乙醇溶液洗脱非极性大孔吸附树脂柱,收集不同浓度乙醇洗脱液,浓缩干燥,即得金腰草提取物B;再用浓度60%-85%的乙醇溶液洗脱极性大孔吸附树脂柱,收集不同浓度乙醇洗脱液,浓缩干燥,即得金腰草提取物C; (3) Pass the drug solution B obtained in step (2) through a non-polar macroporous adsorption resin column, and first elute with water, and the water eluent directly passes through the polar macroporous resin column, and then use a concentration of 60%-95% ethanol solution to elute the non-polar macroporous adsorption resin column, collect ethanol eluents of different concentrations, concentrate and dry, and then obtain Golden Waist Grass Extract B; Hole adsorption resin column, collect ethanol eluents with different concentrations, concentrate and dry, and then get Phalaenopsis extract C;
(4)上述金腰草提取物A、金腰草提取物B、金腰草提取物C混匀,即得本发明的金腰草提取物。 (4) The above-mentioned Golden Waist Grass Extract A, Golden Waist Grass Extract B, and Golden Waist Grass Extract C are mixed evenly to obtain the Golden Waist Grass Extract of the present invention.
优选的金腰草提取物的制备方法为: The preparation method of preferred golden waist extract is:
(1)金腰草,先用浓度90%乙醇作为溶剂,在50℃温浸提取,提取次数为4次,每次提取时间为4小时,每次溶剂用量为金腰草重量的20倍,滤过,得药渣A和提取液,提取液回收乙醇,浓缩,干燥,得金腰草提取物A; (1) Golden waist grass, first use 90% ethanol as a solvent, and extract at 50°C by warm soaking. The number of extractions is 4 times, and the extraction time is 4 hours each time. The amount of solvent used each time is 20 times the weight of golden waist grass. Filtrate to obtain medicinal dregs A and extract, recover ethanol from the extract, concentrate, and dry to obtain Phalaenopsis extract A;
(2)将步骤(1)得到药渣A用浓度30%乙醇为溶剂,在70℃温浸提取,提取次数为3次,每次提取时间为3小时,每次溶剂用量为金腰草重量的15倍,滤过,提取液回收乙醇,浓缩至相对密度d=1.12,滤过,得药液B; (2) Use 30% ethanol as a solvent to extract the dregs A obtained in step (1), warm soaking and extracting at 70°C, the number of extractions is 3 times, and the extraction time is 3 hours each time, and the amount of solvent used each time is the weight of Golden Waist Grass 15 times of that, filtered, the extract recovered ethanol, concentrated to a relative density of d=1.12, filtered to obtain medicinal solution B;
(3)将步骤(2)得到的药液B,通过AB-8非极性大孔吸附树脂柱,先用水洗脱,水洗脱液直接通过DM130极性大孔树脂柱,再用浓度85%的乙醇溶液洗脱AB-8非极性大孔吸附树脂柱,收集85%浓度乙醇洗脱液,浓缩干燥,即得金腰草提取物B;再用浓度的乙醇溶液洗脱DM130极性大孔吸附树脂柱,收集70%浓度乙醇洗脱液,浓缩干燥,即得金腰草提取物C; (3) Pass the drug solution B obtained in step (2) through an AB-8 non-polar macroporous adsorption resin column, and first elute with water, and the water eluate directly passes through a DM130 polar macroporous resin column, and then use a concentration of 85 % ethanol solution to elute AB-8 non-polar macroporous adsorption resin column, collect 85% concentration ethanol eluate, concentrate and dry to obtain Golden Waist Grass Extract B; then elute DM130 polarity with concentration ethanol solution Macroporous adsorption resin column, collecting 70% ethanol eluate, concentrating and drying to obtain Phalaenopsis extract C;
(4)上述金腰草提取物A、金腰草提取物B、金腰草提取物C混匀,即得本发明的金腰草提取物。 (4) The above-mentioned Golden Waist Grass Extract A, Golden Waist Grass Extract B, and Golden Waist Grass Extract C are mixed evenly to obtain the Golden Waist Grass Extract of the present invention.
本发明的金腰草提取物的制备方法,其特征在于:所采用的非极性大孔吸附树脂为AB-8大孔吸附树脂、D101大孔吸附树脂;所采用的极性大孔吸附树脂为DM130大孔吸附树脂、LSA-10大孔吸附树脂。 The preparation method of the golden waist grass extract of the present invention is characterized in that: the nonpolar macroporous adsorption resin adopted is AB-8 macroporous adsorption resin, D101 macroporous adsorption resin; the adopted polar macroporous adsorption resin It is DM130 macroporous adsorption resin and LSA-10 macroporous adsorption resin.
本发明的的金腰草提取物与化学药或中药或天然药物组成治疗糖尿病药物。 The golden waist grass extract of the present invention and chemical medicine or traditional Chinese medicine or natural medicine form the medicine for treating diabetes.
本发明的金腰草提取物A、金腰草提取物B、金腰草提取物C在制备治疗糖尿病药物中的应用。 The application of the golden waist grass extract A, the golden waist grass extract B and the golden waist grass extract C of the present invention in the preparation of medicines for treating diabetes.
本发明的金腰草提取物A、金腰草提取物B、金腰草提取物C与化学药或中药或天然药物组成治疗糖尿病药物。 The golden waist grass extract A, golden waist grass extract B, golden waist grass extract C of the present invention and chemical medicine or traditional Chinese medicine or natural medicine form the medicine for treating diabetes.
本发明的金腰草提取物,通过加入药剂学允许的各种辅料,制成药剂学上的片剂、颗粒剂、胶囊等口服剂型。 The golden waist grass extract of the present invention is prepared into pharmaceutical oral dosage forms such as tablets, granules, and capsules by adding various pharmaceutically acceptable auxiliary materials.
本发明首次对金腰草采用两次吸附树脂纯化技术等进行治疗糖尿病提取物制备研究,分离得到了具有治疗糖尿病活性的提取物,包括金腰草提取物A、金腰草提取物B和金腰草提取物C。 For the first time, the present invention has used two adsorption resin purification techniques for the preparation of the extracts for the treatment of diabetes, and obtained the extracts with the activity of treating diabetes, including the extract A, the extract B and the Waistweed Extract C.
本发明首次以虎耳草科植物裸茎金腰子ChrysospleniumnudicauleBge.及同属数种植物的干燥全草为原料制备提取物用于治疗糖尿病。动物实验表明,金腰草提取物降血糖效果明显。临床观察试验表明,金腰草提取物能明显降低DN患者尿蛋白及血肌醉,改善肾功能。治疗组优于对照组,但对空腹血糖无显著影响(P>0.05)。治疗组治疗后未发现明显不良反应。 For the first time, the present invention uses saxifrage plants Chrysosplenium nudicaule Bge. and dried whole plants of several plants of the same genus as raw materials to prepare extracts for treating diabetes. Animal experiments show that the extract of Golden Waist Grass has obvious hypoglycemic effect. Clinical observation tests have shown that the extract of Golden Waist Grass can significantly reduce urine protein and blood muscle intoxication in patients with DN, and improve renal function. The treatment group was better than the control group, but had no significant effect on fasting blood sugar (P>0.05). No obvious adverse reactions were found in the treatment group after treatment.
具体实施方式 detailed description
下面通过具体实验例和实施例对一种金腰草提取物在制备治疗糖尿病药物中的应用做进一步说明,但不限于本发明。 The following is a further description of the application of a golden waist extract in the preparation of a drug for treating diabetes through specific experimental examples and examples, but it is not limited to the present invention.
实施例1:金腰草提取物的制备 Embodiment 1: the preparation of golden waist grass extract
(1)金腰草16kg,用浓度90%乙醇作为溶剂,在50℃温浸提取,提取次数为4次,每次提取时间为4小时,每次溶剂用量为金腰草重量的20倍,滤过,得药渣A和提取液,提取液回收乙醇,浓缩,干燥,得金腰草提取物A; (1) 16 kg of golden waist grass, use 90% ethanol as solvent, and extract by warm soaking at 50°C, the number of extractions is 4 times, each extraction time is 4 hours, and the amount of solvent used each time is 20 times the weight of golden waist grass, Filtrate to obtain medicinal dregs A and extract, recover ethanol from the extract, concentrate, and dry to obtain Phalaenopsis extract A;
(2)将步骤(1)得到药渣A用浓度30%乙醇为溶剂,在70℃温浸提取,提取次数为3次,每次提取时间为3小时,每次溶剂用量为金腰草重量的15倍,滤过,提取液回收乙醇,浓缩至相对密度d=1.12,滤过,得药液B; (2) Use 30% ethanol as a solvent to extract the dregs A obtained in step (1), warm soaking and extracting at 70°C, the number of extractions is 3 times, and the extraction time is 3 hours each time, and the amount of solvent used each time is the weight of Golden Waist Grass 15 times of that, filtered, the extract recovered ethanol, concentrated to a relative density of d=1.12, filtered to obtain medicinal solution B;
(3)将步骤(2)得到的药液B,通过AB-8非极性大孔吸附树脂柱,先用水洗脱,水洗脱液直接通过DM130极性大孔树脂柱,再用浓度85%的乙醇溶液洗脱AB-8非极性大孔吸附树脂柱,收集85%浓度乙醇洗脱液,浓缩干燥,即得金腰草提取物B;再用浓度70%的乙醇溶液洗脱DM130极性大孔吸附树脂柱,收集70%浓度乙醇洗脱液,浓缩干燥,即得金腰草提取物C; (3) Pass the drug solution B obtained in step (2) through an AB-8 non-polar macroporous adsorption resin column, and first elute with water, and the water eluate directly passes through a DM130 polar macroporous resin column, and then use a concentration of 85 % ethanol solution to elute AB-8 non-polar macroporous adsorption resin column, collect 85% concentration ethanol eluate, concentrate and dry to obtain Golden Waist Grass Extract B; then elute DM130 with 70% ethanol solution Polar macroporous adsorption resin column, collecting 70% ethanol eluate, concentrating and drying to obtain Phalaenopsis extract C;
(4)上述金腰草提取物A、金腰草提取物B、金腰草提取物C混匀,即得本发明的金腰草提取物。 (4) The above-mentioned Golden Waist Grass Extract A, Golden Waist Grass Extract B, and Golden Waist Grass Extract C are mixed evenly to obtain the Golden Waist Grass Extract of the present invention.
实施例2:金腰草提取物的制备 Embodiment 2: the preparation of golden waist grass extract
(1)金腰草24kg,用浓度80%乙醇作为溶剂,在70℃温浸提取,提取次数为2次,每次提取时间为8小时,每次溶剂用量为金腰草重量的30倍,滤过,得药渣A和提取液,提取液回收乙醇,浓缩,干燥,得金腰草提取物A; (1) 24kg of Golden Waist Grass, use 80% ethanol as a solvent, and extract by warm soaking at 70°C. The number of extractions is 2 times, each extraction time is 8 hours, and the amount of solvent used each time is 30 times the weight of Golden Waist Grass. Filtrate to obtain medicinal dregs A and extract, recover ethanol from the extract, concentrate, and dry to obtain Phalaenopsis extract A;
(2)将步骤(1)得到药渣A用水为溶剂,在80℃温浸提取,提取次数为2次,每次提取时间为6小时,每次溶剂用量为金腰草重量的20倍,滤过,提取液浓缩至相对密度d=1.12,滤过,得药液B; (2) The dregs A obtained in step (1) are used as a solvent, soaked and extracted at 80°C, the number of extractions is 2 times, and the extraction time is 6 hours each time, and the amount of solvent used each time is 20 times the weight of the golden waist grass, Filter, concentrate the extract to a relative density of d=1.12, filter to obtain medicinal solution B;
(3)将步骤(2)得到的药液B,通过D101非极性大孔吸附树脂柱,先用水洗脱,水洗脱液直接通过LSA-10极性大孔树脂柱,再用浓度60%的乙醇溶液洗脱D101非极性大孔吸附树脂柱,收集60%浓度乙醇洗脱液,浓缩干燥,即得金腰草提取物B;再用浓度85%的乙醇溶液洗脱LSA-10极性大孔吸附树脂柱,收集85%浓度乙醇洗脱液,浓缩干燥,即得金腰草提取物C; (3) Pass the drug solution B obtained in step (2) through a D101 non-polar macroporous adsorption resin column, and first elute with water. % ethanol solution to elute the D101 non-polar macroporous adsorption resin column, collect the 60% concentration ethanol eluate, concentrate and dry to obtain the golden waist grass extract B; then elute LSA-10 with 85% ethanol solution Polar macroporous adsorption resin column, collect 85% concentration ethanol eluate, concentrate and dry, and obtain Phalaenopsis extract C;
(4)上述金腰草提取物A、金腰草提取物B、金腰草提取物C混匀,即得本发明的金腰草提取物。 (4) The above-mentioned Golden Waist Grass Extract A, Golden Waist Grass Extract B, and Golden Waist Grass Extract C are mixed evenly to obtain the Golden Waist Grass Extract of the present invention.
实施例3:金腰草提取物的制备 Embodiment 3: the preparation of golden waist grass extract
(1)金腰草,用100%乙醇作为溶剂,在20℃温浸提取,提取次数为6次,每次提取时间为2小时,每次溶剂用量为金腰草重量的10倍,滤过,得药渣A和提取液,提取液回收乙醇,浓缩,干燥,得金腰草提取物A; (1) Golden Waist Grass, use 100% ethanol as a solvent, extract by warm soaking at 20°C, the number of extractions is 6 times, each extraction time is 2 hours, and the amount of solvent used each time is 10 times the weight of Golden Waist Grass, filter , to obtain the dregs A and the extract, the extract recovers ethanol, concentrates, and dries to obtain the Phalaenopsis extract A;
(2)将步骤(1)得到药渣A用浓度50%乙醇为溶剂,在30℃温浸提取,提取次数为5次,每次提取时间为1小时,每次溶剂用量为金腰草重量的6倍,滤过,提取液回收乙醇,浓缩至相对密度d=1.05,滤过,得药液B; (2) Use 50% ethanol as a solvent to extract the dregs A obtained in step (1), warm soaking and extracting at 30°C, the number of extractions is 5 times, each extraction time is 1 hour, and the amount of solvent used each time is the weight of Phalaenopsis 6 times of that, filtered, the extract recovered ethanol, concentrated to a relative density of d=1.05, filtered to obtain medicinal solution B;
(3)将步骤(2)得到的药液B,通过AB-8非极性大孔吸附树脂柱,先用水洗脱,水洗脱液直接通过DM130极性大孔树脂柱,再用浓度95%的乙醇溶液洗脱AB-8非极性大孔吸附树脂柱,收集95%浓度乙醇洗脱液,浓缩干燥,即得金腰草提取物B;再用浓度60%的乙醇溶液洗脱DM130极性大孔吸附树脂柱,收集60%浓度乙醇洗脱液,浓缩干燥,即得金腰草提取物C; (3) Pass the drug solution B obtained in step (2) through the AB-8 non-polar macroporous adsorption resin column, and first elute with water, and the water eluate directly passes through the DM130 polar macroporous resin column, and then use a concentration of 95 % ethanol solution to elute AB-8 non-polar macroporous adsorption resin column, collect 95% concentration ethanol eluate, concentrate and dry to obtain Golden Waist Grass Extract B; then elute DM130 with 60% ethanol solution Polar macroporous adsorption resin column, collect 60% concentration of ethanol eluate, concentrate and dry, and obtain Golden Waist Grass Extract C;
(4)上述金腰草提取物A、金腰草提取物B、金腰草提取物C混匀,即得本发明的金腰草提取物。 (4) The above-mentioned Golden Waist Grass Extract A, Golden Waist Grass Extract B, and Golden Waist Grass Extract C are mixed evenly to obtain the Golden Waist Grass Extract of the present invention.
实施例4:金腰草提取物片剂的制备 Embodiment 4: the preparation of Golden Waist Grass Extract Tablet
取实施例1金腰草提取物225g,加入淀粉38g,混匀,制粒,过筛,加微晶纤维素15g,硬脂酸镁1.5g,混匀,压制成1000片,即得金腰草提取物片剂。 Take 225g of Golden Waist Grass extract from Example 1, add 38g of starch, mix evenly, granulate, sieve, add 15g of microcrystalline cellulose, 1.5g of magnesium stearate, mix evenly, and press into 1000 tablets to obtain Golden Waist Herbal Extract Tablets.
实施例5:金腰草提取物颗粒剂的制备 Embodiment 5: Preparation of Golden Waist Grass Extract Granules
取实施例2金腰草提取物195g,加入糊精160g,混匀,制粒,干燥,整粒,即得金腰草提取物颗粒剂。 Take 195 g of the extract of Phyllostachys japonicus in Example 2, add 160 g of dextrin, mix evenly, granulate, dry, and sizing the granules to obtain the extract of Phalaenopsis japonicus granule.
实施例6:金腰草提取物胶囊的制备 Embodiment 6: Preparation of Golden Waist Grass Extract Capsules
取实施例3金腰草提取物235g,加入淀粉85g,混匀,制粒,干燥,整粒,装胶囊1000粒,即得金腰草提取物胶囊。 Take 235 g of the extract of Phyllostachys japonicus in Example 3, add 85 g of starch, mix evenly, granulate, dry, granulate, and pack 1000 capsules to obtain the extract of Phalaenopsis japonicus.
实验例1:金腰草提取物治疗2型糖尿病性肾病微血管病变临床观察试验 Experimental Example 1: Clinical Observational Trial of Golden Waist Grass Extract Treating Microangiopathy in Type 2 Diabetic Nephropathy
临床资料:共观察40例患者,男22例,女18例,平均年龄56岁,全部病例均有10年以上糖尿病病史。所有入选病例均符合WHO1999年颁布的糖尿病诊断标准及高等院校六版教材《内科学》糖尿病肾病的诊断标准。随机分为治疗组、对照组各20例,两组患者在性别、年龄、病程上无显著差异性(P>0.05),具有可比性。所有患者均无急、慢性肾炎及其他肾病,无尿路感染、发热及应用肾毒性药物等。 Clinical data: A total of 40 patients were observed, including 22 males and 18 females, with an average age of 56 years. All patients had a history of diabetes for more than 10 years. All selected cases were in line with the diagnostic criteria for diabetes promulgated by WHO in 1999 and the diagnostic criteria for diabetic nephropathy in the sixth edition textbook "Internal Medicine" for colleges and universities. They were randomly divided into a treatment group and a control group of 20 cases each. There was no significant difference in gender, age, and disease course between the two groups (P>0.05), which were comparable. All patients had no acute or chronic nephritis and other kidney diseases, no urinary tract infection, fever and application of nephrotoxic drugs.
治疗方法:所有患者均先予降压及降糖治疗,降压药物采用血管紧张素转换酶抑制剂(依那普利),降糖药应用胰岛素(甘舒森30R),根据病情调整用量,使空腹血糖降至7mmol/L以下,血压降至18.6/12.0kPa以下。治疗组另予本发明专利实施例4的金腰草提取物制成的片剂,3片/每次,每日3次,2周为1疗程。对照组只用降糖、降压药及对症治疗。观察两组治疗前后空腹血糖(FBG),24h尿蛋白定量、血肌配、内生肌配清除率变化。统计学处理:计数资料用X2检验,计量资料用t检验。 Treatment method: All patients were first given antihypertensive and hypoglycemic treatment, antihypertensive drugs used angiotensin-converting enzyme inhibitors (enalapril), hypoglycemic drugs used insulin (Ganshusen 30R), adjusted dosage according to the condition, so that fasting Blood sugar dropped below 7mmol/L, blood pressure dropped below 18.6/12.0kPa. The treatment group was additionally given tablets made from the extract of Phyllostachys japonicus in the patent example 4 of the present invention, 3 tablets/each time, 3 times a day, and 2 weeks was a course of treatment. The control group only used hypoglycemic, antihypertensive drugs and symptomatic treatment. Observe the changes of fasting blood glucose (FBG), 24-h urine protein quantification, blood-muscle compound clearance rate and endogenous muscle compound clearance rate in the two groups before and after treatment. Statistical processing: count data with X 2 test, measurement data with t test.
治疗结果:两组治疗前后FBG及24h尿蛋白定量、血肌配(SCr)、内生肌配清除率(CCr)的平均值变化。治疗组治疗后比治疗前24h尿蛋白定量、血肌配明显降低(P<0.01),内生肌配清除率明显升高(P<0.01),且与对照组治疗后比较也有显著差异(P<0.01)。表明加用金腰草提取物治疗能明显降低DN患者尿蛋白及血肌醉,改善肾功能。治疗组优于对照组,但对空腹血糖无显著影响(P>0.05)。治疗组治疗后未发现明显不良反应。 Treatment results: the mean changes of FBG and 24h urine protein quantification, SCr and endogenous muscle clearance rate (CCr) in the two groups before and after treatment. After treatment, the 24-h urine protein quantification and blood muscle complex in the treatment group were significantly lower than those before treatment (P<0.01), and the clearance rate of endogenous muscle complex was significantly increased (P<0.01), and there was also a significant difference compared with the control group after treatment (P<0.01). <0.01). It shows that the addition of golden waist grass extract treatment can significantly reduce urine protein and blood muscle intoxication in patients with DN, and improve renal function. The treatment group was better than the control group, but had no significant effect on fasting blood sugar (P>0.05). No obvious adverse reactions were found in the treatment group after treatment.
实验例2:金腰草提取物对自发性肥胖型糖尿病小鼠降血糖试验 Experimental Example 2: Hypoglycemic test of golden waist grass extract on spontaneously obese diabetic mice
实验动物:SPF级,自发性肥胖型糖尿病小鼠(db/db小鼠)60只,6周龄,体重38±2g,随机分组。由中科院动物实验中心提供。 Experimental animals: SPF grade, 60 spontaneously obese diabetic mice (db/db mice), 6 weeks old, weighing 38 ± 2g, were randomly divided into groups. Provided by the Animal Experiment Center of the Chinese Academy of Sciences.
实验药物及仪器:金腰草提取物、金腰草提取物A、金腰草提取物B、金腰草提取物C(实施例1方法制备得到,批号分别为20100303、20100304、20100305、20100306);阳性对照药为马来酸罗格列酮(葛兰素史克天津药业有限公司),onetouchII血糖仪(强生公司)。 Experimental drugs and instruments: Golden Waist Grass Extract, Golden Waist Grass Extract A, Golden Waist Grass Extract B, Golden Waist Grass Extract C (prepared by the method in Example 1, batch numbers are 20100303, 20100304, 20100305, 20100306 respectively) ; Positive control drugs were rosiglitazone maleate (GSK Tianjin Pharmaceutical Co., Ltd.), onetouch II blood glucose meter (Johnson & Johnson).
动物分组:模型对照组:10只,给等量水;阳性对照组:10只,给阳性药;实验药物组:30只,共分为四组,分别给金腰草提取物、金腰草提取物A、金腰草提取物B、金腰草提取物C。 Grouping of animals: model control group: 10 animals, given the same amount of water; positive control group: 10 animals, given positive medicine; experimental drug group: 30 animals, divided into four groups, and given the extracts of Phyllostachys japonicus and Phyllostachys auritifolia respectively. Extract A, Golden Waist Grass Extract B, Golden Waist Grass Extract C.
给药:分组后适应一周开始给药,连续给药2周,给药途径为灌胃。四种提取物的给药量换算为小鼠后为400mg/kg体重,罗格列酮的给药量为5mg/kg体重。 Dosing: After being divided into groups, the dosing starts one week after adaptation, and the dosing lasts for 2 weeks. The dosing route is gavage. The dosage of the four extracts was converted to 400 mg/kg body weight in mice, and the dosage of rosiglitazone was 5 mg/kg body weight.
血糖测定:第7、14天给药1小时后,尾静脉取血用onetouchII血糖仪测定动物随即血糖。试验结果见表1。 Blood glucose measurement: 1 hour after administration on the 7th and 14th day, the blood was taken from the tail vein to measure the blood glucose of the animal immediately with a onetouch II blood glucose meter. The test results are shown in Table 1.
表1金腰草提取物对db/db小鼠血糖浓度的影响 Table 1 The effect of golden waist grass extract on the blood sugar concentration of db/db mice
注:*p<0.05,与模型组比较。 Note: *p<0.05, compared with model group.
表1结果表明各金腰草提取物对db/db小鼠具有显著的降血糖作用,其中金腰草提取物降血糖效果最好。 The results in Table 1 show that the extracts of Phalaenopsis have significant hypoglycemic effects on db/db mice, and the extracts of Phalaenopsis have the best hypoglycemic effect.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310525365.1A CN103585205B (en) | 2013-10-31 | 2013-10-31 | The application of a kind of Chrysosplenium extract in preparation treatment diabetes medicament |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310525365.1A CN103585205B (en) | 2013-10-31 | 2013-10-31 | The application of a kind of Chrysosplenium extract in preparation treatment diabetes medicament |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103585205A CN103585205A (en) | 2014-02-19 |
CN103585205B true CN103585205B (en) | 2016-01-06 |
Family
ID=50075659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310525365.1A Expired - Fee Related CN103585205B (en) | 2013-10-31 | 2013-10-31 | The application of a kind of Chrysosplenium extract in preparation treatment diabetes medicament |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103585205B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103919824B (en) * | 2014-05-08 | 2016-06-29 | 黑龙江中医药大学 | The plant extract of a kind of blood fat reducing and the application in preparing medicine or health product thereof |
-
2013
- 2013-10-31 CN CN201310525365.1A patent/CN103585205B/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
云南的降血糖植物;冯志舟;《云南林业》;20091231;第30卷(第1期);第42页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103585205A (en) | 2014-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101347495B (en) | Preparation method of licorice flavone dispersible tablet | |
CN102861201B (en) | Medicine composition for treating diabetes and preparation method thereof | |
CN103285106B (en) | Traditional Chinese medicinal composition for treating intestinal mucosa damage and preparation method and application thereof | |
CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
CN103585234B (en) | The application of Radix Berberidis Amurensis berry extract in preparation treatment diabetes medicament | |
CN103585205B (en) | The application of a kind of Chrysosplenium extract in preparation treatment diabetes medicament | |
CN105999217A (en) | Composition for preventing and treating hyperuricemia as well as preparation method and application of composition | |
CN102228666B (en) | Composition prepared from pine pollen and curcuma, preparation method thereof, and application of composition in preparing medicament for treating inflammatory bowel disease | |
CN106421559B (en) | A kind of traditional Chinese medicine preparation for treating hyperuricemia and preparation method thereof | |
CN103735621A (en) | A traditional Chinese medicine composition capable of lowering blood fat and enhancing immunity | |
CN107007702A (en) | A kind of Chinese medicine composition and its preparation for treating osteoarthropathy | |
CN103585302B (en) | The application of the extracts such as a kind of Song Sheng in preparation treatment diabetes medicament | |
CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
CN101856375B (en) | Preparation method and application of effective component of trumpetcreeper | |
CN110755601A (en) | Kidney bean agglutinin plant medicine composition for treating HIV/AIDS immune reconstitution defect and preparation method and application thereof | |
CN106563076B (en) | Medicine for treating stomach disease and its preparing method | |
CN117379505B (en) | Traditional Chinese medicine composition for treating chronic kidney disease | |
CN102688254B (en) | Medicinal composition for treating chronic diarrhea and preparation method and use thereof | |
CN111068024A (en) | A kind of traditional Chinese medicine compound preparation and preparation method thereof | |
CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
CN101869604B (en) | Preparation method and application of cortex meliae effective ingredients | |
CN101658646B (en) | Pharmaceutical composition for curing summer-heat cold and preparation method thereof | |
CN1981812B (en) | Chinese-medicinal preparation for treating AIDS and its production | |
CN100361662C (en) | A kind of preparation method of Chinese medicine composition preparation | |
CN119303021A (en) | A turbidity-clearing and detoxifying Chinese medicine composition for improving insulin resistance and a preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: He Xingliang Inventor before: Kong Qianqian |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151209 Address after: Sujiatun District of Shenyang City 110102 jinqiansong East Road No. 36 in Liaoning Province Applicant after: Shenyang Sport University Address before: 250101 No. 51 Industrial South Road, Ji'nan hi tech Zone, Shandong, Ji'nan Applicant before: Jinan Xingyi Medical Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160106 Termination date: 20161031 |
|
CF01 | Termination of patent right due to non-payment of annual fee |